Ashland Inc. (NYSE:ASH – Free Report) – Research analysts at Seaport Res Ptn decreased their Q2 2025 earnings per share estimates for Ashland in a report issued on Wednesday, January 29th. Seaport Res Ptn analyst M. Harrison now anticipates that the basic materials company will post earnings per share of $1.22 for the quarter, down from their previous forecast of $1.27. The consensus estimate for Ashland’s current full-year earnings is $4.27 per share. Seaport Res Ptn also issued estimates for Ashland’s Q3 2025 earnings at $1.51 EPS, Q4 2025 earnings at $1.51 EPS, FY2025 earnings at $4.52 EPS and FY2026 earnings at $5.89 EPS.
Ashland (NYSE:ASH – Get Free Report) last announced its earnings results on Tuesday, January 28th. The basic materials company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.79 by ($0.51). Ashland had a negative net margin of 1.12% and a positive return on equity of 7.41%. During the same period in the previous year, the company earned $0.45 EPS.
Get Our Latest Stock Analysis on ASH
Ashland Trading Down 4.2 %
Shares of NYSE ASH opened at $60.85 on Monday. Ashland has a 12 month low of $60.60 and a 12 month high of $102.50. The company has a market cap of $2.87 billion, a price-to-earnings ratio of -92.20, a P/E/G ratio of 1.11 and a beta of 0.87. The company has a quick ratio of 1.27, a current ratio of 2.52 and a debt-to-equity ratio of 0.51. The business has a fifty day simple moving average of $72.19 and a 200-day simple moving average of $81.28.
Ashland Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Saturday, March 15th. Stockholders of record on Saturday, March 1st will be issued a dividend of $0.405 per share. This represents a $1.62 dividend on an annualized basis and a dividend yield of 2.66%. The ex-dividend date is Friday, February 28th. Ashland’s dividend payout ratio is -245.45%.
Insider Activity
In other news, CEO Guillermo Novo acquired 31,294 shares of Ashland stock in a transaction on Friday, January 31st. The stock was bought at an average price of $64.24 per share, for a total transaction of $2,010,326.56. Following the transaction, the chief executive officer now owns 31,294 shares of the company’s stock, valued at $2,010,326.56. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Eric N. Boni sold 451 shares of the firm’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $78.07, for a total value of $35,209.57. Following the completion of the sale, the vice president now owns 14,182 shares of the company’s stock, valued at $1,107,188.74. This represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. 1.02% of the stock is currently owned by insiders.
Institutional Trading of Ashland
A number of hedge funds have recently modified their holdings of ASH. Prospera Private Wealth LLC bought a new stake in shares of Ashland in the 3rd quarter worth approximately $31,000. UMB Bank n.a. lifted its position in shares of Ashland by 193.1% in the 3rd quarter. UMB Bank n.a. now owns 381 shares of the basic materials company’s stock worth $33,000 after acquiring an additional 251 shares during the period. Versant Capital Management Inc bought a new position in shares of Ashland during the 4th quarter worth approximately $33,000. Wilmington Savings Fund Society FSB bought a new position in shares of Ashland during the 3rd quarter worth approximately $38,000. Finally, Assetmark Inc. lifted its position in shares of Ashland by 610.5% during the 3rd quarter. Assetmark Inc. now owns 540 shares of the basic materials company’s stock worth $47,000 after buying an additional 464 shares during the period. Institutional investors own 93.95% of the company’s stock.
Ashland Company Profile
Ashland Inc provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions.
Recommended Stories
- Five stocks we like better than Ashland
- 3 Best Fintech Stocks for a Portfolio Boost
- How to Invest in Small Cap Stocks
- What is the Dow Jones Industrial Average (DJIA)?
- These Are the Dividend Stocks Insiders Bought in January
- What is the Hang Seng index?
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for Ashland Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ashland and related companies with MarketBeat.com's FREE daily email newsletter.